Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Patent
1995-06-07
1999-09-21
Reeves, Julie
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
4241331, 4241391, 4241411, 4241521, 5303871, 5303881, 5303882, A61K 39395
Patent
active
059550759
ABSTRACT:
A new gene--MN--and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides.
REFERENCES:
patent: 5387676 (1995-02-01), Zavada et al.
Uemura et al., "Expression of Tumor-Associated Antigen MN/G250 in Urologic Carcinoma: Potential Therapeutic Target," J. Urology: 157 (4 Supp): 377 (Abstract 1475) (Apr. 16, 1997).
Bodey et al., "Human Cancer Detection and Immunotherapy with Conjugated and Non-Conjugated Monoclonal Antibodies," Anticancer Research, 16: 661-674 (1996).
Chan and Sikora, "The potential of oncogene products as tumour markers," Cancer Surveys, 6(2): 185-207 (1987).
DeVita et al. (eds.), Biologic Therapy of Cancer (Second Edition), Chapter 21: "Clinical Applications of Monoclonal Antibodies in Cancer," pp. 553-623 (J. P. Lippincott Company, Philadelphia; 1995).
Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen," PNAS (USA) 33: 9129-9133 (Dec. 1986).
Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo," Oncogene, 2: 273-277 (1988).
Drebin et al., "Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo," Oncogene, 2: 387-394 (1988).
Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic," Journal of Clinical Immunology, 11(3): 117-127 (1991).
Svoboda, J., "Malignant Interaction of Rous Virus With Mammalian Cells In Vivo and In Vitro," National Cancer Institute Monograph No. 17, IN: "International Conference on Avian Tumor Virus" (J. W. Beard ed.), pp. 277-298 (1964).
Divgi et al., "Scintigraphy of Renal Cell Carcinoma with I-131 Labelled Monoclonal Antibody (MAB) G250," European Journal of Nuclear Medicine, 19(8): 578 (Abstract) (Aug. 23, 1992).
Kurth et al., "Characterization of Human Renal Cell Carcinoma Tumor Lines by means of Monoclonal Antibodies," Prostate, 6(4): 451 (Abstract 1985).
Oosterwijk et al., "The Expression of Renal Antigens in Renal Cell Carcinoma," World Journal of Urology, 2(2): 156-158 (1984).
Oosterwijk et al., "Monoclonal Antibodies that Discriminate Between Renal Cell Carcinomas (RCC) and other Malignancies," Prostate, 6(4): 451-452 (1985).
Oosterwijk et al., "Immunohistochemical Analysis of Monoclonal Antibodies to Renal Antigens--Application in the Diagnosis of Renal Cell Carcinoma," American Journal of Pathology, 123(2): 301-309 (May 1986).
Oosterwijk et al., "Monoclonal Antibody G250 Recognizes a Determinant Present in Renal-Cell Carcinoma and Absent from Normal Kidney," Int. J. Cancer, 38: 489-494 (1986).
Oosterwijk et al., "Relationship Between DNA Ploidy, Antigen Expression and Survival in Renal Cell Carcinoma," Int. J. Cancer, 42: 703-708 (1988).
Oosterwijk et al., "Expression of Intermediate-sized Filaments in Developing and Adult Human Kidney and Renal Cell Carcinoma," The Journal of Histochemistry and Cytochemistry, 38(3): 385-392 (1990).
Oosterwijk et al., "Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250," Journal of Clinical Oncology, 11(4): 738-750 (Apr. 1993).
Oosterwijk et al., "The Use of Monoclonal Antibody G250 in the Therapy of Renal-Cell Carcinoma," Seminars in Oncology, 22(1): 34-41 (Feb. 1995).
Oosterwijk et al., "Molecular characterization of the Renal Cell Carcinoma-associated antigen G250," Proceedings of the American Association for Cancer Research, 37: 461 (Mar. 1996).
Uemura et al., "Internal Image Anti-Idiotype Antibodies Related to Renal-Cell Carcinoma-Associated Antigen G250," Int. J. Cancer, 56: 609-614 (1994).
Uemura et al., "Vaccination with Anti-Idiotype Antibodies Mimicking a Renal Cell Carcinoma-Associated Antigen Induces Tumor Immunity," Int. J. Cancer, 58: 555-561 (1994).
Uemura et al., "Immunization with Anti-Idiotype Monoclonal Antibodies Bearing the Internal Image of the Renal-Cell Carcinoma-Associated Antigen G25 Induces Specific Cellular Immune Responses," Int. J. Cancer, 59: 802-807 (1994).
Uemura et al., "Anti-tumor effects of vaccination with internal image anti-idotype monoclonal antibodies," Biotherapy (Japan), 9(3): 294-295 (1995).
Van Dijk et al., "Therapeutic Effects of Monoclonal Antibody G250, Interferons and Tumor Necrosis Factor, In Mice with Renal-Cell Carcinoma Xenografts," Int. J. Cancer, 56: 262-268 (1994).
Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer," PNAS (USA), 85: 8998-9002 (Dec. 1988).
Liao et al., "Identification of the Mn Antigen as a Diagnostic Biomarker of Cervical Intraepithelial Squamous and Glandular Neoplasia and Cervical Carcinomas," American Journal of Pathology, 145(3): 598-609 (Sep. 1994).
Pastorek et al., "Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment," Oncogene, 9: 2877-2888 (1994).
Opavsky et al., "Regulation of MN Expression," Cell Biology International, 18(5): Abstract No. Mo-58 (1994).
Frosch et al., "Cloning and Characterisation of an Immunodominant Major Surface Antigen of Echinococcus multilocularis", Molecular and Biochemical Parasitology, 48: 121-130 (1991).
Pastorekova et al., "A Novel Quasi-viral Agent, MaTu, Is a Two-Component System", Virology, 187: 620-626 (1992).
Stanbridge et al., "Specific Chromosome Loss Associated with the Expression of Tumorigenicity in Human Cell Hybrids", Somatic Cell Genetics, 7(6): 699-712 (1981).
Stanbridge et al., "Human Cell Hybrids: Analysis of Transformation and Tumorigenicity", Science, 215: 252-259 (Jan. 15, 1982).
Tweedie and Edwards, "Mouse Carbonic Anhydrase III: Nucleotide Sequence and Expression Studies", Biochemical Genetics, 27(1/2): 17-30 (1989).
Young and Davis, "Efficient Isolation of Genes by Using Antibody Probes", PNAS (USA) 80: 1194-1198 (Mar. 1983).
Zavada, "The Pseudotypic Paradox", J. gen. Virol., 63: 15-24 (1982).
Zavada and Zavadova, "A Transmissible Antigen Detected in Two Cell Lines Derived from Human Tumours", J. gen. Virol., 24: 327-337 (1974).
Zavada and Zavadova, "An unusual transmissible agent--MaTu", Arch. Virol., 118: 189-197 (1991).
Zavada et al., "VSV Pseudotype Produced in Cell Line derived from Human Mammary Carcinoma", Nature New Biology, 240: 124-125 (Nov. 22, 1972).
Zavada et al., "Tumorigenicity-Related Expression of MaTu Proteins in HeLa x Fibroblast Hybrids", Abstract presented at the XIX Meeting of the European Tumor Virus Group (May 1-4, 1991).
Zavada et al., "Expression of MaTu-MN Protein in Human Tumor Cultures and in Clinical Specimens", Int. J. Cancer, 54: 268-274 (1993).
Pastorekova et al., "MN--A Novel Type of Oncoprotein," Cell Biology International, 18(5): Abstract No. Mo-57 (1994).
Pastorekova et al., "Transformation of Mammalian Cells by MN Oncogene," Cell Biology International, 18(5): Abstract No. Mo-56 (1994).
Bander et al., "Renal cancer imaging with monoclonal antibody G250," Proc. Am. Urol. Assoc., 155 (Suppl.): 583A (Abstract 1088; May 1996).
Dillman, R.O., "Review: Monoclonal Antibodies for Treating Cancer," Annals of Internal Medicine, 111(7): 592-602 (1989).
Divgi et al., "Radioimmunotherapy with I-131-G250 in Metastatic Renal Cell Cancer (RCC)" J. Nucl. Med., 36 (5 Suppl.): 913P (Abstract 956; May 1995).
Nakagawa et al., "MN as a Potential Target in Renal Cell Carcinoma," J. Urology,
Pastorek Jaromir
Pastorekova Silvia
Zavada Jan
Ebert Ray F.
Institute of Virology Slovak Academy of Sciences
Lauder Leona L.
Morgenstern Arthur S.
Reeves Julie
LandOfFree
Method of inhibiting tumor growth using antibodies to MN protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting tumor growth using antibodies to MN protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting tumor growth using antibodies to MN protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-77560